278 related articles for article (PubMed ID: 32246968)
1. No evidence of increased cancer incidence in children using topical tacrolimus for atopic dermatitis.
Paller AS; Fölster-Holst R; Chen SC; Diepgen TL; Elmets C; Margolis DJ; Pollock BH
J Am Acad Dermatol; 2020 Aug; 83(2):375-381. PubMed ID: 32246968
[TBL] [Abstract][Full Text] [Related]
2. Topical tacrolimus for atopic dermatitis.
Cury Martins J; Martins C; Aoki V; Gois AF; Ishii HA; da Silva EM
Cochrane Database Syst Rev; 2015 Jul; 2015(7):CD009864. PubMed ID: 26132597
[TBL] [Abstract][Full Text] [Related]
3. Cancer risk with topical calcineurin inhibitors, pimecrolimus and tacrolimus, for atopic dermatitis: a systematic review and meta-analysis.
Devasenapathy N; Chu A; Wong M; Srivastava A; Ceccacci R; Lin C; MacDonald M; Wen A; Steen J; Levine M; Pyne L; Schneider L; Chu DK;
Lancet Child Adolesc Health; 2023 Jan; 7(1):13-25. PubMed ID: 36370744
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of topical calcineurin inhibitors in the treatment of childhood atopic dermatitis.
Breuer K; Werfel T; Kapp A
Am J Clin Dermatol; 2005; 6(2):65-77. PubMed ID: 15799678
[TBL] [Abstract][Full Text] [Related]
5. [Long term management of childhood atopic dermatitis with calcineurin inhibitors].
Thaçi D
Hautarzt; 2003 May; 54(5):418-23. PubMed ID: 12719861
[TBL] [Abstract][Full Text] [Related]
6. Association Between Malignancy and Topical Use of Pimecrolimus.
Margolis DJ; Abuabara K; Hoffstad OJ; Wan J; Raimondo D; Bilker WB
JAMA Dermatol; 2015 Jun; 151(6):594-9. PubMed ID: 25692459
[TBL] [Abstract][Full Text] [Related]
7. Topical calcineurin inhibitors in the treatment of atopic dermatitis - an update on safety issues.
Czarnecka-Operacz M; Jenerowicz D
J Dtsch Dermatol Ges; 2012 Mar; 10(3):167-72. PubMed ID: 21974750
[TBL] [Abstract][Full Text] [Related]
8. Long-term safety of tacrolimus ointment in atopic dermatitis.
Remitz A; Reitamo S
Expert Opin Drug Saf; 2009 Jul; 8(4):501-6. PubMed ID: 19435404
[TBL] [Abstract][Full Text] [Related]
9. Risk of lymphoma in patients with atopic dermatitis and the role of topical treatment: A systematic review and meta-analysis.
Legendre L; Barnetche T; Mazereeuw-Hautier J; Meyer N; Murrell D; Paul C
J Am Acad Dermatol; 2015 Jun; 72(6):992-1002. PubMed ID: 25840730
[TBL] [Abstract][Full Text] [Related]
10. [Safety of topical tacrolimus and pimecrolimus in children with atopic dermatitis].
Rodríguez Orozco AR; Ruiz Reyes H; Marín Hernández D
Rev Alerg Mex; 2005; 52(4):171-6. PubMed ID: 16268186
[TBL] [Abstract][Full Text] [Related]
11. Topical treatments with pimecrolimus, tacrolimus and medium- to high-potency corticosteroids, and risk of lymphoma.
Schneeweiss S; Doherty M; Zhu S; Funch D; Schlienger RG; Fernandez-Vidaurre C; Seeger JD
Dermatology; 2009; 219(1):7-21. PubMed ID: 19293564
[TBL] [Abstract][Full Text] [Related]
12. Tacrolimus ointment. A review of its therapeutic potential as a topical therapy in atopic dermatitis.
Cheer SM; Plosker GL
Am J Clin Dermatol; 2001; 2(6):389-406. PubMed ID: 11770393
[TBL] [Abstract][Full Text] [Related]
13. Association between exposure to topical tacrolimus or pimecrolimus and cancers.
Hui RL; Lide W; Chan J; Schottinger J; Yoshinaga M; Millares M
Ann Pharmacother; 2009 Dec; 43(12):1956-63. PubMed ID: 19903860
[TBL] [Abstract][Full Text] [Related]
14. Effect of sequential applications of topical tacrolimus and topical corticosteroids in the treatment of pediatric atopic dermatitis: an open-label pilot study.
Kubota Y; Yoneda K; Nakai K; Katsuura J; Moriue T; Matsuoka Y; Miyamoto I; Ohya Y
J Am Acad Dermatol; 2009 Feb; 60(2):212-7. PubMed ID: 19027990
[TBL] [Abstract][Full Text] [Related]
15. Three times weekly tacrolimus ointment reduces relapse in stabilized atopic dermatitis: a new paradigm for use.
Paller AS; Eichenfield LF; Kirsner RS; Shull T; Jaracz E; Simpson EL;
Pediatrics; 2008 Dec; 122(6):e1210-8. PubMed ID: 19015204
[TBL] [Abstract][Full Text] [Related]
16. Tacrolimus and pimecrolimus: from clever prokaryotes to inhibiting calcineurin and treating atopic dermatitis.
Nghiem P; Pearson G; Langley RG
J Am Acad Dermatol; 2002 Feb; 46(2):228-41. PubMed ID: 11807435
[TBL] [Abstract][Full Text] [Related]
17. Tacrolimus ointment for the treatment of adult and pediatric atopic dermatitis: Review on safety and benefits.
Ohtsuki M; Morimoto H; Nakagawa H
J Dermatol; 2018 Aug; 45(8):936-942. PubMed ID: 29927498
[TBL] [Abstract][Full Text] [Related]
18. Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children.
Remitz A; Harper J; Rustin M; Goldschmidt WF; Palatsi R; van der Valk PG; Sharpe G; Smith CH; Dobozy A; Turjanmaa K;
Acta Derm Venereol; 2007; 87(1):54-61. PubMed ID: 17225017
[TBL] [Abstract][Full Text] [Related]
19. Systematic review of published trials: long-term safety of topical corticosteroids and topical calcineurin inhibitors in pediatric patients with atopic dermatitis.
Siegfried EC; Jaworski JC; Kaiser JD; Hebert AA
BMC Pediatr; 2016 Jun; 16():75. PubMed ID: 27267134
[TBL] [Abstract][Full Text] [Related]
20. Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis.
Arellano FM; Wentworth CE; Arana A; Fernández C; Paul CF
J Invest Dermatol; 2007 Apr; 127(4):808-16. PubMed ID: 17096020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
